CATABASIS PHARMACEUTICALS IN's ticker is and the CUSIP is 14875P206. A total of 53 filers reported holding CATABASIS PHARMACEUTICALS IN in Q2 2020. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2021 | $311,000 | +1051.9% | 107,600 | +760.8% | 0.01% | +500.0% |
Q4 2020 | $27,000 | -95.2% | 12,500 | -86.2% | 0.00% | -92.3% |
Q3 2020 | $559,000 | -3.8% | 90,300 | 0.0% | 0.01% | +8.3% |
Q2 2020 | $581,000 | +154.8% | 90,300 | +64.2% | 0.01% | +140.0% |
Q1 2020 | $228,000 | +101.8% | 55,000 | +163.2% | 0.01% | +150.0% |
Q3 2019 | $113,000 | -33.1% | 20,900 | 0.0% | 0.00% | 0.0% |
Q2 2019 | $169,000 | – | 20,900 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Fairmount Funds Management LLC | 4,092,166 | $8,634,000 | 3.55% |
COMMODORE CAPITAL LP | 1,617,000 | $3,412,000 | 1.19% |
ACUTA CAPITAL PARTNERS, LLC | 1,173,674 | $2,476,000 | 0.99% |
VR Adviser, LLC | 3,234,000 | $6,824,000 | 0.83% |
Logos Global Management LP | 3,190,000 | $6,731,000 | 0.57% |
Cormorant Asset Management, LP | 3,550,000 | $7,490,000 | 0.25% |
Soleus Capital Management, L.P. | 775,000 | $1,635,000 | 0.25% |
Perceptive Advisors | 15,374,370 | $32,438,000 | 0.21% |
RA Capital Management | 5,947,861 | $12,550,000 | 0.20% |
SILVERARC CAPITAL MANAGEMENT, LLC | 188,777 | $398,000 | 0.18% |